Venous Thrombosis Recurrence After Catheter-Related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Retrospective Analysis.

IF 2.6 3区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Angiology Pub Date : 2024-08-01 Epub Date: 2023-05-17 DOI:10.1177/00033197231176985
Rabiaa Hakem, Simon Soudet, Momar Diouf, Marie Antoinette Sevestre
{"title":"Venous Thrombosis Recurrence After Catheter-Related Upper Extremity Deep Venous Thrombosis in Cancer Patients: A Retrospective Analysis.","authors":"Rabiaa Hakem, Simon Soudet, Momar Diouf, Marie Antoinette Sevestre","doi":"10.1177/00033197231176985","DOIUrl":null,"url":null,"abstract":"<p><p>Long-term indwelling central venous catheters (CVC) are frequently used to secure vascular access to deliver injectable treatment. Catheter-related thrombosis (CRT) occurs in approximately 2-6% of cancer patients. We conducted a single-center retrospective study to assess the rate of venous thromboembolism (VTE) recurrence in cancer patients; 200 patients were included. Mean age was 56 ± 15.15 years, median follow-up duration was 16.5 [range: 10-36] months. The incidence of recurrence was estimated using Gray's method for competing risk with death as the competing event of VTE. Recurrent VTE occurred in 25.5% of patients with a median occurrence time of 6.5 [range: 5-11.25] months. In case of recurrence, 94.6% of patients were treated for cancer and 80.4% of them received anticoagulants; 4 major bleeds and 17 non-major bleeds occurred during follow-up. In multivariate analysis, previous VTE (Hazard Ratio (HR) 2.48 (95% CI 1.42-4.32) and presence of CVC (HR 5.56 (95% CI 1.96-15.75) were significant recurrence risk factors. After a first episode of CRT, 25.5% of patients experienced VTE recurrence as UEDVT in 30 cases (55.5%), PE in 17 cases (31.5%), and DVT in 7 cases (13%), mostly during anticoagulation therapy. Anticoagulation therapy does not avoid CRT in case of cancer and must be balanced with hemorrhagic risk.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197231176985","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Long-term indwelling central venous catheters (CVC) are frequently used to secure vascular access to deliver injectable treatment. Catheter-related thrombosis (CRT) occurs in approximately 2-6% of cancer patients. We conducted a single-center retrospective study to assess the rate of venous thromboembolism (VTE) recurrence in cancer patients; 200 patients were included. Mean age was 56 ± 15.15 years, median follow-up duration was 16.5 [range: 10-36] months. The incidence of recurrence was estimated using Gray's method for competing risk with death as the competing event of VTE. Recurrent VTE occurred in 25.5% of patients with a median occurrence time of 6.5 [range: 5-11.25] months. In case of recurrence, 94.6% of patients were treated for cancer and 80.4% of them received anticoagulants; 4 major bleeds and 17 non-major bleeds occurred during follow-up. In multivariate analysis, previous VTE (Hazard Ratio (HR) 2.48 (95% CI 1.42-4.32) and presence of CVC (HR 5.56 (95% CI 1.96-15.75) were significant recurrence risk factors. After a first episode of CRT, 25.5% of patients experienced VTE recurrence as UEDVT in 30 cases (55.5%), PE in 17 cases (31.5%), and DVT in 7 cases (13%), mostly during anticoagulation therapy. Anticoagulation therapy does not avoid CRT in case of cancer and must be balanced with hemorrhagic risk.

癌症患者导管引起的上肢深静脉血栓后的静脉血栓复发:回顾性分析
长期留置的中心静脉导管(CVC)常用于确保血管通路,以进行注射治疗。约有 2-6% 的癌症患者会发生导管相关血栓 (CRT)。我们进行了一项单中心回顾性研究,评估癌症患者静脉血栓栓塞症(VTE)复发率,共纳入 200 名患者。平均年龄为(56 ± 15.15)岁,中位随访时间为 16.5 个月(10-36 个月)。采用格雷竞争风险法估算复发率,死亡作为 VTE 的竞争事件。25.5%的患者复发了 VTE,中位发生时间为 6.5 个月[范围:5-11.25 个月]。在复发的患者中,94.6%的患者接受了癌症治疗,80.4%的患者接受了抗凝治疗;随访期间发生了4次大出血和17次非大出血。在多变量分析中,既往 VTE(危险比 (HR) 2.48 (95% CI 1.42-4.32))和存在 CVC(HR 5.56 (95% CI 1.96-15.75))是重要的复发风险因素。在首次接受 CRT 治疗后,25.5% 的患者出现了 VTE 复发,其中 30 例(55.5%)为 UEDVT,17 例(31.5%)为 PE,7 例(13%)为 DVT,大部分是在抗凝治疗期间复发的。抗凝治疗并不能避免癌症患者的 CRT,必须与出血风险相平衡。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Angiology
Angiology 医学-外周血管病
CiteScore
5.50
自引率
14.30%
发文量
180
审稿时长
6-12 weeks
期刊介绍: A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信